taVNS for FRNS in Children
A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children
Northwell Health
30 participants
Jan 5, 2023
INTERVENTIONAL
Conditions
Summary
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.
Eligibility
Inclusion Criteria7
- FRNS
- Age 3-17 years
- Glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m2
- Minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) diagnosis (clinical diagnosis or per biopsy)
- Steroid sensitive nephrotic syndrome (prior history of remission within 4 weeks of steroid therapy)
- In remission at time of enrollment (remission defined as UPC \<0.2 or negative dipstick for 3 consecutive days)
- Informed consent from the parent or guardian and assent from a minor of ≥ 7. years
Exclusion Criteria10
- Secondary forms of nephrotic syndrome
- SRNS
- Steroid dependent nephrotic syndrome (relapse within 14 days of stopping steroids or relapse while on steroids)
- Exposure to steroids within 14 days of enrollment
- Receiving any standing immunosuppression (previous exposure \> 2 months allowed and/or B cell repletion)
- Any known inflammatory condition (e.g. systemic lupus erythematosis)
- History of cardiac disease (arrhythmias, structural/functional abnormalities)
- Implantable electronic devices
- Pregnancy
- Participants/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
The device will appear to function but no electrical stimulation will be delivered.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05588063